FDA Clears First RAS-Targeting Pill for Metastatic Pancreatic Cancer

The Food and Drug Administration approved daraxonrasib last week, giving patients with metastatic pancreatic adenocarcinoma their first oral RAS inhibitor and what trial data describe as a meaningful, if still measured, survival benefit over standard chemotherapy.

The drug, sold by Revolution Medicines under the brand name Rasonque, targets the RAS protein, a key driver of tumor growth that has resisted therapeutic interference for decades. <cite index="16-3">FDA officials gave expedited approval to the first-of-a-kind pill, which blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases.</cite> The agency cleared the drug nearly six and a half months ahead of its original goal date, according to an FDA press announcement reviewed for this story.

<cite index="9-1">The approval covers adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent systemic therapy.</cite> That's a narrower population than the headline might suggest: these are patients who've already been through first-line treatment and whose cancer has kept moving.

The trial results, published in the New England Journal of Medicine and cited in filings reviewed from the Oncology Nursing Society and Memorial Sloan Kettering Cancer Center, are the clearest reason for the clinical interest. <cite index="11-9,11-10,11-11">The international phase 3 trial enrolled 500 patients with metastatic pancreatic cancer who had been previously treated. Roughly half received daraxonrasib and the other half received chemotherapy of the investigator's choice. Median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, and median progression-free survival was 7.2 months versus 3.6 months.</cite>

Those aren't cure numbers. But in a disease where a diagnosis of metastatic pancreatic cancer still carries a five-year survival rate in the single digits, doubling median survival in the second-line setting is a result that oncologists have been waiting a long time to see.

The tolerability data also stand out. <cite index="11-12,11-13">The drug's side effects, including skin rashes and gastrointestinal issues, were mostly manageable. They were severe enough to stop treatment in 1.2% of daraxonrasib patients, compared with 11.2% of those on chemotherapy.</cite> For patients who've already been through one round of systemic treatment, that difference in discontinuation rates matters in ways a press release doesn't fully capture.

<cite index="15-4">Rasonque, taken as a tablet once daily, targets multiple forms of a protein called RAS, a key driver of tumor growth in most patients with pancreatic adenocarcinoma, which arises from cells lining the ducts of the pancreas.</cite> It's a mechanistic approach that's been described as "undruggable" in the oncology community for decades. The fact that it works, at least in this population, in this trial, is the scientific headline.

The practical one is cost. <cite index="16-6">A one-month supply would cost approximately $39,800, the company announced.</cite> For a drug that produced a median overall survival of just over 13 months, that puts the full course of treatment well into six figures before insurance, copay programs, or prior authorization battles enter the picture. Patients already weakened by first-line therapy and the disease itself will now need to navigate that system to reach a pill they take once a day at home.

<cite index="9-6,9-7">The FDA conducted the review under Project Orbis, an Oncology Center of Excellence initiative that provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with Health Canada, and the European Medicines Agency and Japan's Pharmaceuticals and Medical Devices Agency were official observers.</cite> Regulatory review in those jurisdictions hasn't concluded yet.

For now, the approval gives oncologists a real second-line option in a cancer type that's had precious few. The survival numbers from the RASolute 302 trial are worth taking seriously. So is the question of who can actually get the drug once they leave the clinic.

Sources cited:
- FDA press announcement (https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer)
- FDA drug approval page (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma)
- Oncology Nursing Society (https://www.ons.org/publications-research/voice/news-views/08-2026/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma)
- Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/news/how-daraxonrasib-could-improve-pancreatic-cancer-treatment-offering-new-hope)
- NPR (https://www.npr.org/2026/08/27/g-s1-140410/fda-approves-landmark-pancreatic-cancer-drug)